FOXP3 rs2280883 polymorphism confers susceptibility to colorectal cancer in a Chinese Han population.


Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
15 Apr 2020
Historique:
received: 24 10 2019
revised: 22 01 2020
accepted: 23 01 2020
pubmed: 29 1 2020
medline: 4 3 2020
entrez: 29 1 2020
Statut: ppublish

Résumé

Studies imply the FOXP3 gene polymorphisms are engaged in the occurrence of some cancers, but the relationship between FOXP3 rs2280883 polymorphism and the hazard of colorectal cancer (CRC) is unclear. For this reason, a case-control investigation involving 365 CRC patients and 411 healthy individuals (matched by both age and gender) was taken to illustrate the underlying association. FOXP3 rs2280883 polymorphism genotyped via PCR-RELP. Data revealed this polymorphism was significantly linked to increased risk for CRC (CC versus TT, OR, 1.75; 95%CI, 1.06-2.88; P = 0.030). Subgroup analyses uncovered FOXP3 rs2280883 polymorphism intensified the risk of CRC among smokers. As for the connection between rs2280883 and clinical data of CRC, this polymorphism corelated to lymph node metastasis (CC versus TT: OR, 2.75; 95%CI, 1.35-5.62; P = 0.004) and the TNM stage. In conclusion, FOXP3 rs2280883 polymorphism is related to higher risk of CRC in a Chinese individuals. Larger-sized studies involving other races are needed.

Identifiants

pubmed: 31987907
pii: S0378-1119(20)30064-0
doi: 10.1016/j.gene.2020.144395
pii:
doi:

Substances chimiques

FOXP3 protein, human 0
Forkhead Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144395

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ying Lou (Y)

Department of Medical Oncology, Zhuji People's Hospital of Zhejiang Province, The Zhuji affiliated Hospital of Shaoxing University, Zhuji, Zhejiang 311800, China.

Minhui Fan (M)

Department of Pharmacy, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.

Renya Shuai (R)

Department of Pharmacy, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.

Cheng Yao (C)

Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Electronic address: yaoc1010@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH